could be but would only happen on a big positive COAST result to pay for more market preparations. wouldnt be a problem IMO. The longer they keep the drug in house and get ready for market the more money they can make in the end, by takeover from Pfizer or others, licensing multiple players nonexclusively or going to market themselves.
Ann: Opthea Completes Placement & Institutional Entitlement Offer, page-10
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $806.3M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |